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1996 and 2011. A clinical and ultrasound follow-up was achieved in
31 patients with a mean follow-up period of 43±26 months. 
Results: The mean age of patients was 43±11 years [23, 63]. 87,5% of the
population being female (5 men and 35 women). The immediate procedural
success was achieved in 31 patients (77.5%). A severe mitral regurgitation
(MR) was observed in 3 patients (7.5%). A cerebrovascular stroke occurred in
1 patient (2.5%). No procedure-related death or cardiac tamponade were
noted. Only a left atrial area ≤25cm ² was linked to high risk of severe MR.
At long-term, mitral restenosis was observed in 13 patients (42%) at 53±30
months [9; 128] after re-PMV, 2 patients presented thromboembolic events (6%)
and no death. Only the male had been identified as a predictor of restenosis 
Conclusion: The feasibility of re – PMV with a relatively high procedural
success rate and an acceptable complication profile makes it an appealing
therapeutic strategy for patients with recurrent valve stenosis. The improved
experience of our medical teams, and the systematic use of transoesophageal
echocardiography to detect thrombi explain the low incidence of the compli-
cations of re-PMV in our study. 
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Aims: Benfluorex’s imputability in drug-induced valvular heart disease
(DIVHD) is now well established. However no data about long term clinical
and echocardiographic follow-up of patients suffering from benfluorex-
related DIVHD are available. The present study was conducted to address
this issue.
Methods and results: Between January 2003 and June 2012, after an
exhaustive analysis of our database, 20 patients (55±9 years, 90% women,
body mass index: 32.9±9 kg/m²) hospitalized for heart failure were retrospec-
tively identified with benfluorex induced moderate or severe mitral regurgita-
tion (MR). Initially 70% of them presented NYHA class III or IV. MR was
quantified as moderate in 11, moderate to severe in 8 and severe in one
patient. Aortic regurgitation (AR) was also present in 17 patients (85%): mild
in 5, moderate in 9 and moderate to severe in 3 patients. During a median
follow-up of 7 years, heart failure episodes led to 53388 Valve replacements.
Two patients died, one in the surgical group and one in the medical group.
Among survivors, NYHA class improved in 6 patients in the surgical group
but only in 4 in the medical group. After withdrawal of benfluorex, MR
decreased in 7 patients and AR decreased in 5 patients. MR was stable in
3 patients and AR in 4 patients. A worsening of MR was not observed and AR
worsened in 2 patients. 
Conclusion: After an hospitalization for a first episode of heart failure
related to benfluorex-induced MR, patients are exposed to a large number of
cardiac events including repeated hospitalizations and death. 
